PCI-32765 Form A Crystallization via Seed-Assisted Anti-Solvent

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods are inadequate for large-scale industrial production of PCI-32765 crystalline Form A, lacking stability and reliability.

Innovation Solution

A preparation method involving dissolving PCI-32765 free base in a solvent like methanol, adding it to an anti-solvent such as water with seed crystals, and controlling temperature and aging to produce a stable crystalline Form A suitable for industrial production.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Manufacturing precision

If the prior art preparation method of PCI-32765 Form A is used, then the crystal form can be obtained in lab test, but it cannot be scaled up for industrial large-scale production

Engineering Contradiction:
Improvecrystal form purityVSAvoidproduction scale
Core Design Contradiction:
Manufacturing precisionVSProductivity

Solution Approach 1:

The patent modifies critical process parameters including solvent composition (methanol/water ratio), temperature profile (0-20°C range), and addition rate to enable scalable production while maintaining crystal form purity. The optimized parameters allow consistent formation of Form A crystals from lab to industrial scale.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent introduces seed crystals of PCI-32765 Form A before adding the anti-solvent to initiate controlled crystallization. This preliminary action ensures that the desired crystal form is established early in the process, enabling reliable scale-up while maintaining manufacturing precision.

Inventive Principle:
Principle #10Preliminary action

2Reliability

If the prior art preparation method is used, then crystal Form A can be produced, but the method lacks stability and reliability for consistent production

Engineering Contradiction:
Improveproduction consistencyVSAvoidprocess control
Core Design Contradiction:
ReliabilityVSEase of manufacture

Solution Approach 1:

The patent implements monitoring and control of key parameters including temperature maintenance (0-20°C), pH control during crystallization, and visual observation of crystal formation. These feedback mechanisms ensure consistent production of Form A while maintaining ease of manufacture through straightforward process control.

Inventive Principle:
Principle #23Feedback

Solution Approach 2:

The patent employs dynamic control of the anti-solvent addition rate and temperature adjustment during crystallization to optimize crystal formation. This dynamic approach enhances production consistency while keeping the manufacturing process manageable and controllable.

Inventive Principle:
Principle #15Dynamics

3Productivity

If rapid crystallization is performed to increase productivity, then production speed increases, but crystal quality and impurity removal deteriorate

Engineering Contradiction:
Improvecrystallization speedVSAvoidcrystal quality
Core Design Contradiction:
ProductivityVSManufacturing precision

Solution Approach 1:

The patent employs periodic or controlled addition of anti-solvent rather than rapid single-step addition. This controlled approach maintains reasonable productivity while ensuring adequate time for high-quality crystal formation and impurity exclusion, achieving both speed and precision.

Inventive Principle:
Principle #19Periodic action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The method allows for stable, scalable, and high-yield production of PCI-32765 crystalline Form A with good impurity removal and suitable hygroscopicity and solubility for medicinal use.

Implementation Method 1

Adding dropwise the solution prepared by step 1) into an anti-solvent, the anti-solvent being pure water, then stirring at a temperature of 0∼20 °C and adding seed crystals of PCI-32765 Form A

Methodology Applied
Scientific EffectCrystallization: Crystallisation

Implementation Method 2

Adding dropwise the solution prepared by step 1) into an anti-solvent, the anti-solvent being pure water

Methodology Applied
Scientific EffectAnti-solvent precipitation: Precipitation

Implementation Method 3

Filtering the crystal slurry of step 3) to obtain a filter cake

Methodology Applied
Scientific EffectFiltration: Filter (physical)

Implementation Method 4

washing and drying the filter cake to obtain a powder of PCI-32765 Form A

Methodology Applied
Scientific EffectWashing:

Implementation Method 5

washing and drying the filter cake to obtain a powder of PCI-32765 Form A

Methodology Applied
Scientific EffectDrying: Desiccation

Data Source

PatentEP3272753B1Preparation method of PCI-32765 crystal form a
Publication Date: 2020.03.04 CRYSTAL PHARMATECH CO LTD
  • EP3272753B1 patent drawingFigure 1~2
  • EP3272753B1 patent drawingFigure 3~4
  • EP3272753B1 patent drawing

AI summary

A preparation method of PCI-32765 crystalline form A, which comprises the following steps: 1) dissolving free base of PCI-32765 in a good solvent; 2) the solution prepared by Step 1) is dropwise added into an anti-solvent, stirred and added seed crystal of PCI-32765 Form A; Or the solution prepared by Step 1) is dropwise added into the suspension containing seed crystal of PCI-32765 Form A; 3) solution obtained by step 2) is continuously stirred and aged until crystal transformation is completed, then the crystal slurry is obtained; 4) crystal slurry in step 3) is filtered, washed, and dried to obtain the powder of PCI-32765 Form A. The preparation method of crystalline Form A provided by the present disclosure has simple process and can be easily controlled, scaled up stably and reliably. The process has high yield, good impurity removing capacity and is environmentally friendly. In addition, Form A provided by the present disclosure can be stably stored, and the hygroscopicity and solubility of Form A meet the requirements for medicinal use.